United-Guardian, Inc. logo

United-Guardian, Inc. (UG)

Market Closed
17 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
7. 55
+0.05
+0.6667%
$
33.1M Market Cap
15.04 P/E Ratio
0.35% Div Yield
9,600 Volume
0 Eps
$ 7.5
Previous Close
Investors:
Add Transaction
Day Range
7.5 7.59
Year Range
5.58 9.88
Want to track UG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
UG Outperforms Industry in 6 Months: Buy, Sell or Hold the Stock?

UG Outperforms Industry in 6 Months: Buy, Sell or Hold the Stock?

United-Guardian's rally reflects stronger sales, distribution expansion and recovering cosmetic demand, but valuation and trade risks may limit its near-term appeal.

Zacks | 1 week ago
United-Guardian Q1 Earnings Rise Y/Y on Strong Renacidin Demand

United-Guardian Q1 Earnings Rise Y/Y on Strong Renacidin Demand

UG reports higher y/y earnings and sales in Q1, driven by strong demand for Renacidin and increased purchases of cosmetic ingredients.

Zacks | 2 months ago
United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript

United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript

United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript

Seekingalpha | 2 months ago
United-Guardian 2025 Earnings Fall Y/Y Amid Weak Sales Trends

United-Guardian 2025 Earnings Fall Y/Y Amid Weak Sales Trends

UG reports a sharp drop in 2025 earnings as weak cosmetic sales weigh on results, despite growth in pharmaceuticals and medical lubricants.

Zacks | 3 months ago
UG Q3 Profit Falls Y/Y on Weak Cosmetics Sales, Stock Declines 10%

UG Q3 Profit Falls Y/Y on Weak Cosmetics Sales, Stock Declines 10%

United-Guardian's Q3 earnings fall y/y on weak cosmetic sales, pressuring margins and sending UG shares down even as pharma and medical lines grow.

Zacks | 8 months ago
UG Q2 Earnings Fall Y/Y on Weak Cosmetic Sales, Pharma Gains

UG Q2 Earnings Fall Y/Y on Weak Cosmetic Sales, Pharma Gains

United-Guardian's Q2 earnings fall on weak cosmetic sales, partly offset by gains in pharmaceuticals and medical lubricants, with recovery hopes ahead.

Zacks | 11 months ago
United-Guardian Q1 Earnings Fall 39% Y/Y as Cosmetic Sales Tumble 63%

United-Guardian Q1 Earnings Fall 39% Y/Y as Cosmetic Sales Tumble 63%

UG's Q1 earnings drop 39% as cosmetic sales plunge, offsetting gains in pharmaceuticals and medical lubricants.

Zacks | 1 year ago
United-Guardian Stock Dips 9.6% Despite Robust 2024 Sales & Earnings

United-Guardian Stock Dips 9.6% Despite Robust 2024 Sales & Earnings

UG's 2024 sales grow 12% y/y and earnings rise. Yet. the stock falls amid supply challenges and muted guidance, sparking mixed investor sentiment.

Zacks | 1 year ago
United-Guardian Reports Y/Y Rise in Q3 Earnings, Flat Revenues

United-Guardian Reports Y/Y Rise in Q3 Earnings, Flat Revenues

UG's Q3 earnings gain from effective cost management and increased demand for its cosmetic ingredients segment.

Zacks | 1 year ago
United-Guardian (UG) Posts Y/Y Q2 Earnings & Sales Growth

United-Guardian (UG) Posts Y/Y Q2 Earnings & Sales Growth

Higher cosmetic ingredient sales aid United-Guardian's (UG) earnings in Q2.

Zacks | 1 year ago
Zacks Initiates Coverage of United-Guardian With Outperform Recommendation

Zacks Initiates Coverage of United-Guardian With Outperform Recommendation

Discover why Zacks rates United-Guardian (UG) as "Outperform," being the first on Wall Street to initiate the coverage of the stock. Explore UG's robust growth in cosmetic ingredient sales, a strong financial foundation and promising product launches, making it an attractive option for investors.

Zacks | 2 years ago